TAVR Insurance Denied? How to Appeal

Transcatheter aortic valve replacement (TAVR) - also called TAVI (transcatheter aortic valve implantation) - has revolutionized the treatment of severe aortic stenosis. It offers a minimally invasive alternative to open-heart surgery (SAVR) for patients across the full spectrum of surgical risk. Despite its growing role as The Standard of care for many patients with severe aortic stenosis, TAVR denials do occur - and they deserve a strong, structured response.

TAVR vs. SAVR: Understanding the Choice

Aortic stenosis is a condition in which the aortic valve narrows, restricting blood flow from the heart to the body. Severe symptomatic aortic stenosis carries a poor prognosis without valve replacement. The two primary treatment options are:

Surgical aortic valve replacement (SAVR): Open-heart surgery requiring cardiopulmonary bypass and sternotomy. The traditional gold standard but carries significant risk in elderly or frail patients or those with significant comorbidities.

Transcatheter aortic valve replacement (TAVR): The valve is delivered via catheter, typically through the femoral artery, without open-chest surgery. Initially approved only for patients at extreme or high surgical risk, TAVR has expanded to intermediate and low surgical risk patients based on clinical trial data.

The choice between TAVR and SAVR is made by a multidisciplinary Heart Team - typically involving interventional cardiologists, cardiac surgeons, imaging specialists, and other clinicians - after assessing the patient's anatomy, comorbidities, surgical risk score, and patient preference.

Why Insurers Deny TAVR

Surgical risk criteria not clearly met. Historically, insurers required documentation of high or intermediate surgical risk (as measured by validated risk scores such as the STS PROM score or the EuroSCORE II) before approving TAVR over SAVR. As TAVR has expanded to lower-risk patients, some insurers have not updated their coverage criteria to reflect current evidence and guidelines, resulting in denials for patients who would clearly benefit.

Heart Team evaluation not documented. Medicare's coverage policy for TAVR explicitly requires a multidisciplinary Heart Team evaluation and a documented recommendation. If the medical record does not include this documentation, the claim may be denied on procedural grounds even when the clinical indication is clear.

Anatomic unsuitability for SAVR not established. Some insurers specifically require documentation that SAVR is contraindicated or excessively risky, rather than simply suboptimal. This requires explicit statements in the clinical notes and surgical risk assessment.

Imaging and anatomic criteria not documented. TAVR requires specific anatomic criteria - aortic annulus dimensions, vascular access adequacy, absence of prohibitive calcification patterns - typically assessed by cardiac CT. If the pre-procedural imaging workup is incomplete or not documented in the appeal file, the insurer may deny on the basis of inadequate pre-procedural evaluation.

TAVR classified as not superior to medical therapy. For truly asymptomatic severe aortic stenosis, the evidence base for TAVR is still evolving, and insurers may deny on the basis that intervention has not been demonstrated to be superior to watchful waiting. If symptoms are present, this must be clearly documented.

Building Your TAVR Appeal

Step 1: Establish the severity of aortic stenosis with imaging data.

Your appeal should include:

• Echocardiogram report documenting severe aortic stenosis (aortic valve area, mean gradient, peak velocity)
• Confirmation of symptomatic status (chest pain/angina, syncope or pre-syncope, heart failure symptoms/dyspnea)
• Cardiac CT report documenting valve anatomy, annulus dimensions, and vascular access planning

Step 2: Document the Heart Team evaluation.

Include a signed Heart Team note or multidisciplinary conference note that:

• Lists the participating specialists
• Summarizes the patient's clinical profile and risk assessment
• States the recommendation for TAVR over SAVR with rationale
• References the surgical risk score (STS PROM) and its value

Step 3: Quantify surgical risk.

Include the formal STS risk score calculation and, if applicable, additional risk factors not captured by the STS score (frailty, hostile chest, porcelain aorta, prior radiation, severe COPD, hepatic dysfunction) that the Heart Team considered in elevating the effective surgical risk.

Step 4: Document SAVR risk or contraindication.

The cardiac surgeon's note should explicitly state whether SAVR is contraindicated, high-risk, or associated with expected poor outcomes - and why. For low-risk patients, the appeal should reference trial data demonstrating non-inferiority or superiority of TAVR over SAVR for appropriate anatomical and clinical profiles.

Step 5: Reference current guidelines and coverage policies.

The ACC/AHA Guidelines on Valvular Heart Disease provide specific recommendations for TAVR. Cite the applicable Class I or IIa recommendation. Also reference the relevant Medicare National Coverage Determination (NCD) for TAVR, which outlines the specific coverage criteria including Heart Team requirements.

Step 6: Provide a physician letter of medical necessity

Related Reading

• 5 Reasons Insurance Companies Deny Claims (And How to Fight Back)
• Abdominoplasty Insurance Claim Denied? How to Appeal (Medical Necessity)
• Abortion Insurance Coverage Denied? How to Appeal
• Accelerated Death Benefit Denied? How to Appeal
• Accident Insurance Claim Denied? How to Appeal